Cidara’s pursuit of universal flu protection with a single dose
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
Cidara’s pursuit of universal flu protection with a single dose
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Every year, flu vaccine manufacturers have to guess what strains to target next season, with varying success. Cidara Therapeutics believes it may have a better alternative. President and CEO Jeff Stein explains how Cidara's laser-like focus on developing CD388, a single-dose antiviral targeting all flu strains, has brought the 40-person company on the verge of a public health breakthrough.
Cidara announces positive topline results from its phase 2b NAVIGATE trial evaluating CD388
President and CEO Jeff Stein Bio
Pas encore de commentaire